Author:
Ambrosini Anna,Schoenen Jean
Publisher
Springer International Publishing
Reference107 articles.
1. Lipton RB, Silberstein SD (1994) Why study the comorbidity of migraine? Neurology 44:4–5
2. Silberstein SD, Winner PK, Chmiel JJ (2003) Migraine preventive medication reduces resource utilization. Headache 43:171–178
3. Tfelt-Hansen P, Pascual J, Ramadan N et al; International Headache Society Clinical Trials Subcommittee (2012) Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 32:6–38
4. Lipton RB, Diamond M, Freitag F et al (2005) Migraine prevention patterns in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 45:792–793 (Abstract)
5. Silberstein SD, Latsko M, Schoenen J (2012) Preventive antimigraine drugs. In: Fernandez-de-las-Penas C, Chaitow L, Schoenen J (eds) Multidisciplinary management of migraine. Jones & Bartlett Learning, Burlington, pp 91–102